Methods and compositions for the treatment of pain utilizing ropivacaine

• US 5,834,489 A
• Filed: 05/05/1997
• Issued: 11/10/1998
• Est. Priority Date: 06/28/1993
• Status: Expired due to Term

• Current Assignee: Fresenius KABI USA LLC (Fresenius SE & Co. KGaA)
• Original Assignee: Ab Astra
• Inventors: Eek, Arne Torsten
• Primary Examiner(s): Henley, III, Raymond
• Application Number:
  US08/851,062
• Time in Patent Office: 554 Days
• Field of Search: 514/330
• US Class Current: 514/330
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 23/02 Local anaesthetics
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.

Claims

1. A method of treating a human so as to relieve pain with minimal motor blockade, said method comprising epidurally administering to said human a composition comprising a pharmaceutically acceptable salt of ropivacaine, wherein said ropivacaine is present in said composition at a concentration of less than 0.5% by weight.

2. The method of claim 1, wherein said ropivacaine is present in said composition at a concentration of between 0.01% and 0.45% by weight.

3. The method of claim 1, wherein said ropivacaine is present in said composition at a concentration of between 0.01% and 0.3% by weight.

4. The method of claim 1, wherein said ropivacaine is present in said composition at a concentration of about 0.25%.

5. The method of claim 1, wherein said ropivacaine is present in said composition at a concentration of about 0.3%.

6. The method of claim 1, wherein said pharmaceutically acceptable salt of ropivacaine is ropivacaine hydrochloride.

7. The method of any one of claims 1-6, wherein said composition is administered by continuous infusion.